Idelalisib (Zydelig®)

Assessment Status Assessment process complete
Drug Idelalisib
Brand Zydelig®
Indication In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
Assessment Process
Rapid review commissioned 08/12/2014
Rapid review completed 30/12/2014
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 04/06/2015
NCPE assessment completed 16/02/2016
NCPE assessment outcome Reimbursement not recommended.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations December 2016.